Literature DB >> 11078419

Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway.

L P Eberl1, G Egidy, F Pinet, L Juillerat-Jeanneret.   

Abstract

An imbalance between proliferation and apoptosis is important in tumor progression. Endothelin-1 (ET-1) has vasoconstricting and mitogenic activities and may be involved in apoptosis regulation. We found that ET-1 and FasL systems were colocalized in human colon tumors and that ET-1 was secreted by human (HT-29, SW480) and rat (PROb, REGb) colon carcinoma cell lines. Bosentan, a mixed endothelin-A- and -B- (ET(A)/ET(B)) receptor antagonist, potentiated FasL- (APO-1, CD95) induced apoptosis in these cells. The specific inhibition of enzymes involved in ceramide production did not restore survival of cells exposed to FasL and bosentan. Inhibition of PKC with bisindolylmaleimide IX enhanced FasL-induced apoptosis in HT-29, PROb and REGb cells in the absence of bosentan. These results suggest that ET-1 is an autocrine survival factor able to protect colon carcinoma cells against FasL-induced apoptosis, involving the protein kinase C (PKC) but not the sphingomyelin-ceramide signaling transduction pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078419     DOI: 10.1097/00005344-200036051-00103

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Authors:  Longwei Qiao; Yuting Liang; Na Li; Xiaoxia Hu; Dongwei Luo; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Seok Joong Yun; Junqin He; Emily Brantley; Dominic Fan; Panja Strickner; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

3.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

4.  Endothelin-1 inhibits apoptosis in prostate cancer.

Authors:  Joel B Nelson; Michael S Udan; Georgi Guruli; Beth R Pflug
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

5.  Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease.

Authors:  Silvia Kelsen; John E Hall; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-06

Review 6.  Current Pharmacological Approach to ARDS: The Place of Bosentan.

Authors:  Omer Araz
Journal:  Eurasian J Med       Date:  2020-02

7.  Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.

Authors:  Edwin Herrmann; Arne Tiemann; Elke Eltze; Christian Bolenz; Christoph Bremer; Thorsten Persigehl; Lothar Hertle; Christian Wülfing
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-09       Impact factor: 4.553

8.  Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.

Authors:  Ahmet Dirican; Yuksel Kucukzeybek; Ahmet Alacacioglu; Umut Varol; Saliha Aksun; Ibrahim Vedat Bayoglu; Lutfiye Demir; Eyup Coban; Recep Sutcu; Mustafa Oktay Tarhan
Journal:  Med Oncol       Date:  2014-03-05       Impact factor: 3.064

9.  Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.

Authors:  L A Lambert; A R Whyteside; A J Turner; B A Usmani
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

10.  Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  P Wülfing; J Tio; C Kersting; B Sonntag; H Buerger; C Wülfing; U Euler; W Boecker; A H Tulusan; L Kiesel
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.